Business Description
BioNTech SE
ISIN : US09075V1026
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 67.93 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.82 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 6.82 | |||||
Beneish M-Score | -4.91 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 93.7 | |||||
3-Year EPS without NRI Growth Rate | 151.4 | |||||
3-Year Book Growth Rate | 137.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -7.99 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 54.49 | |||||
9-Day RSI | 61.63 | |||||
14-Day RSI | 63.53 | |||||
6-1 Month Momentum % | -0.89 | |||||
12-1 Month Momentum % | -21.14 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.54 | |||||
Quick Ratio | 7.4 | |||||
Cash Ratio | 7.13 | |||||
Days Inventory | 303.06 | |||||
Days Sales Outstanding | 231.5 | |||||
Days Payable | 315.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.5 | |||||
Shareholder Yield % | 1.17 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 82.94 | |||||
Operating Margin % | -29.26 | |||||
Net Margin % | -18.6 | |||||
FCF Margin % | 87.43 | |||||
ROE % | -2.53 | |||||
ROA % | -2.24 | |||||
ROIC % | -28.82 | |||||
3-Year ROIIC % | 16.31 | |||||
ROC (Joel Greenblatt) % | -28.99 | |||||
ROCE % | -2.53 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 13.49 | |||||
PS Ratio | 9.26 | |||||
PB Ratio | 1.3 | |||||
Price-to-Tangible-Book | 1.39 | |||||
Price-to-Free-Cash-Flow | 10.65 | |||||
Price-to-Operating-Cash-Flow | 8.43 | |||||
EV-to-EBIT | -14.93 | |||||
EV-to-Forward-EBIT | -4.49 | |||||
EV-to-EBITDA | -25.01 | |||||
EV-to-Forward-EBITDA | -5.21 | |||||
EV-to-Revenue | 2.87 | |||||
EV-to-Forward-Revenue | 2.38 | |||||
EV-to-FCF | 3.3 | |||||
Price-to-Projected-FCF | 0.57 | |||||
Price-to-Net-Current-Asset-Value | 1.64 | |||||
Price-to-Net-Cash | 1.76 | |||||
Earnings Yield (Greenblatt) % | -6.7 | |||||
FCF Yield % | 9.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
BioNTech SE Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2,690.6 | ||
EPS (TTM) (€) | -2.11 | ||
Beta | 0.46 | ||
Volatility % | 30.06 | ||
14-Day RSI | 63.53 | ||
14-Day ATR (€) | 3.752837 | ||
20-Day SMA (€) | 89.9 | ||
12-1 Month Momentum % | -21.14 | ||
52-Week Range (€) | 69.6 - 114.8 | ||
Shares Outstanding (Mil) | 237.77 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BioNTech SE Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BioNTech SE Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
BioNTech SE Frequently Asked Questions
What is BioNTech SE(WBO:BNTX)'s stock price today?
When is next earnings date of BioNTech SE(WBO:BNTX)?
Does BioNTech SE(WBO:BNTX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |